{"id":68833,"date":"2026-06-24T23:45:51","date_gmt":"2026-06-24T15:45:51","guid":{"rendered":"https:\/\/flcube.com\/?p=68833"},"modified":"2026-06-24T23:45:52","modified_gmt":"2026-06-24T15:45:52","slug":"mabwell-secures-nmpa-clinical-trial-approval-for-6mw5311-bispecific-antibody-dual-us-china-authorization-for-hematological-malignancies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68833","title":{"rendered":"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mabwell Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2493:HKG\">HKG: 2493<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>clinical trial approval<\/strong> for its investigational <strong>6MW5311 bispecific antibody<\/strong> for the treatment of <strong>hematological malignancies<\/strong>, including <strong>acute myeloid leukemia (AML)<\/strong>, <strong>chronic myelomonocytic leukemia (CMML)<\/strong>, and <strong>multiple myeloma (MM)<\/strong>. The candidate had previously received clinical trial authorization from the <strong>U.S. Food and Drug Administration (FDA)<\/strong>, establishing dual regulatory clearance in the world&#8217;s two largest pharmaceutical markets.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>6MW5311 bispecific antibody (investigational)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>AML, CMML, and MM<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>24 Jun 2026<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Approved for clinical trials in both US (FDA) and China (NMPA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> T-cell engager (TCE) technology platform<\/li>\n\n\n\n<li><strong>Molecular Architecture:<\/strong> <strong>&#8220;2+1&#8221; asymmetric structure<\/strong> simultaneously targeting <strong>LILRB4<\/strong> (tumor antigen) and <strong>CD3<\/strong> (T-cell receptor)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Features a <strong>unique steric hindrance design<\/strong> that minimizes CD3 binding to T cells in the absence of tumor cells<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Bridges tumor cells and T cells to form an <strong>immunological synapse<\/strong>, activating T cells exclusively in the tumor microenvironment<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Enables <strong>tumor-specific T-cell activation<\/strong>, enhancing anti-tumor efficacy while substantially improving safety profile compared to conventional T-cell engaging antibodies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-amp-development-evidence\" class=\"wp-block-heading\">Preclinical &amp; Development Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>6MW5311 Innovation<\/th><th>Conventional T-cell Engagers<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Specificity<\/strong><\/td><td>LILRB4\/CD3 bispecific with tumor-dependent activation<\/td><td>Often lack tumor microenvironment specificity<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Reduced off-tumor T-cell activation due to steric hindrance design<\/td><td>Higher risk of cytokine release syndrome and on-target\/off-tumor toxicity<\/td><\/tr><tr><td><strong>Efficacy Potential<\/strong><\/td><td>Enhanced tumor-specific killing through immunological synapse formation<\/td><td>Variable efficacy depending on tumor antigen density<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Dual-approved for clinical trials (US FDA + China NMPA)<\/td><td>Multiple candidates in various stages of development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Preclinical data demonstrated that 6MW5311&#8217;s innovative steric hindrance design significantly reduces non-specific T-cell activation, potentially mitigating common adverse events associated with T-cell engaging therapies while maintaining potent anti-tumor activity.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hematological Malignancy Landscape:<\/strong> AML, CMML, and MM represent significant unmet medical needs with limited treatment options, particularly for relapsed\/refractory patients<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Dual regulatory approval positions Mabwell to conduct global clinical trials and potentially achieve simultaneous market access in US and China<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> The tumor-specific activation mechanism addresses a key limitation of existing T-cell engagers, potentially offering improved safety without compromising efficacy<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success of 6MW5311 would validate Mabwell&#8217;s proprietary TCE technology platform for future bispecific antibody development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, manufacturing challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062301530_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026062301530_c.\"><\/object><a id=\"wp-block-file--media-2814f044-031b-47ee-8d6e-3387e8bb6092\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062301530_c.pdf\">2026062301530_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062301530_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2814f044-031b-47ee-8d6e-3387e8bb6092\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,62,4705,118,2790],"class_list":["post-68833","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-2493","tag-mabwell-bioscience","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational 6MW5311 bispecific antibody for the treatment of hematological malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). The candidate had previously received clinical trial authorization from the U.S. Food and Drug Administration (FDA), establishing dual regulatory clearance in the world&#039;s two largest pharmaceutical markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68833\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies\" \/>\n<meta property=\"og:description\" content=\"Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational 6MW5311 bispecific antibody for the treatment of hematological malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). The candidate had previously received clinical trial authorization from the U.S. Food and Drug Administration (FDA), establishing dual regulatory clearance in the world&#039;s two largest pharmaceutical markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68833\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-24T15:45:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-24T15:45:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68833#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68833\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies\",\"datePublished\":\"2026-06-24T15:45:51+00:00\",\"dateModified\":\"2026-06-24T15:45:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68833\"},\"wordCount\":445,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2493\",\"Mabwell Bioscience\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68833#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68833\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68833\",\"name\":\"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-24T15:45:51+00:00\",\"dateModified\":\"2026-06-24T15:45:52+00:00\",\"description\":\"Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational 6MW5311 bispecific antibody for the treatment of hematological malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). The candidate had previously received clinical trial authorization from the U.S. Food and Drug Administration (FDA), establishing dual regulatory clearance in the world's two largest pharmaceutical markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68833#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68833\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68833#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational 6MW5311 bispecific antibody for the treatment of hematological malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). The candidate had previously received clinical trial authorization from the U.S. Food and Drug Administration (FDA), establishing dual regulatory clearance in the world's two largest pharmaceutical markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68833","og_locale":"en_US","og_type":"article","og_title":"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies","og_description":"Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational 6MW5311 bispecific antibody for the treatment of hematological malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). The candidate had previously received clinical trial authorization from the U.S. Food and Drug Administration (FDA), establishing dual regulatory clearance in the world's two largest pharmaceutical markets.","og_url":"https:\/\/flcube.com\/?p=68833","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-24T15:45:51+00:00","article_modified_time":"2026-06-24T15:45:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68833#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68833"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies","datePublished":"2026-06-24T15:45:51+00:00","dateModified":"2026-06-24T15:45:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68833"},"wordCount":445,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 2493","Mabwell Bioscience","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68833#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68833","url":"https:\/\/flcube.com\/?p=68833","name":"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-24T15:45:51+00:00","dateModified":"2026-06-24T15:45:52+00:00","description":"Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational 6MW5311 bispecific antibody for the treatment of hematological malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). The candidate had previously received clinical trial authorization from the U.S. Food and Drug Administration (FDA), establishing dual regulatory clearance in the world's two largest pharmaceutical markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68833#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68833"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68833#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody \u2013 Dual US-China Authorization for Hematological Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68833"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68833\/revisions"}],"predecessor-version":[{"id":68835,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68833\/revisions\/68835"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}